Demystifying Macrogenics: Insights From 14 Analyst Reviews
Demystifying Macrogenics: Insights From 14 Analyst Reviews
揭開宏觀經濟的神祕面紗：來自14條分析師評論的見解
Analysts' ratings for Macrogenics (NASDAQ:MGNX) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
14位分析師提供的分析師對Macrogenics（納斯達克股票代碼：MGNX）在上個季度的評級從看漲到看跌不等。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您將找到他們最近的評級摘要，揭示了過去30天中情緒的變化，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Macrogenics, presenting an average target of $17.57, a high estimate of $29.00, and a low estimate of $4.00. Highlighting a 7.18% decrease, the current average has fallen from the previous average price target of $18.93.
在對12個月目標股價的評估中，分析師公佈了對Macrogenics的見解，將平均目標價定爲17.57美元，最高估計爲29.00美元，低估值爲4.00美元。當前的平均價格已低於之前的平均目標價18.93美元，跌幅爲7.18％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
The standing of Macrogenics among financial...
通過對分析師...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。